Biopharma
ByIs Novo Nordisk Positioning Cell-Based Therapies as the Future of Diabetes Care?
23 January 2026 Executive Summary Novo Nordisk has expanded its strategic collaboration with Canadian biotech Aspect Biosystems, intensifying…
Is Novo Nordisk Facing Legal Scrutiny Over Diabetes Drug Market Conduct?
23 January 2026 Executive Summary Novo Nordisk is facing a new class-action lawsuit in the U.S., filed by…
Is Novo Nordisk’s Oral Wegovy Off to a Record Start? Early Prescription Surge Signals Strong Momentum
23 January 2026 Executive Summary Novo Nordisk’s newly launched oral Wegovy weight-loss therapy has recorded a robust debut,…
Roche Doubles Down on U.S. Biomanufacturing: $2 Billion Investment to Advance Next-Generation Therapies
23 January 2026 Executive Summary Roche’s Genentech unit announced a major expansion of its biomanufacturing facility in Holly…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst Ahead?
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
